Company Profile CuspAI

Building generative AI for materials discovery,

· Company profiles,Generative AI

Executive Summary — CuspAI

CuspAI, a two-year-old Cambridge, UK startup building generative AI for materials discovery, closed a $450 million Series B on July 20, 2026, at a $2.6 billion valuation — roughly five times its valuation just ten months earlier. The round was co-led by Kleiner Perkins and NEA, with Jeff Bezos's Bezos Expeditions and the UK government's Sovereign AI Venture Fund investing side by side, alongside AMD Ventures, Temasek, and others. Total funding to date exceeds $670 million.

Founded in 2024 by chemist Chad Edwards and AI researcher Max Welling, CuspAI's pitch inverts traditional materials science: instead of synthesizing a compound and testing its properties, its models take target properties as input and generate candidate molecular structures — aimed at reducing chipmakers' dependence on scarce metals like iridium and ruthenium, alongside applications in batteries, water treatment, and carbon capture. Commercial traction so far includes named partnerships with Hyundai, Meta, Kemira, and ASML.

Alongside the raise, CuspAI launched the "AI Materials Foundry," a 45+ member industry coalition including Nvidia, Meta, Samsung, and Hyundai, pooling compute and data for materials research — a bid to position the company as infrastructure for the field, not just another vendor in it.

The investor mix is the more telling signal than the number itself: chip-industry capital (AMD Ventures), sovereign wealth (Temasek, the UK fund), and marquee US VCs all in the same round reflects a broader 2026 pattern of capital chasing AI applied to physical-world problems rather than pure software — the same thesis Bezos is betting on at far larger scale elsewhere (a separate startup, Prometheus, reportedly raised $12B at a $41B valuation around the same period). What remains unproven at this valuation is whether CuspAI's technology can actually compress materials-discovery timelines at industrial scale — the commercial partnerships are real signals of interest, but none of the public reporting describes a fully validated deployment yet.